Skip to main content
. Author manuscript; available in PMC: 2021 May 4.
Published in final edited form as: Am J Hematol. 2020 Sep 23;95(11):1269–1279. doi: 10.1002/ajh.25941

TABLE 2.

CYB5R3 mutation status in the three cohorts studied. Results in number (%)

Mutation status Zambian children with malaria (N = 165) PUSH: US SCD children/ adolescents (N = 267) Walk-PHaSST: US/ UKSCD adolescents/ adults (N = 321)
CYB5R3 wildtype subjects 75 (45.5%) 136 (50.9%) 148 (46.1%)
CYB5R3c350C > G heterozygotes 78 (47.3%) 109 (40.8%) 135 (42.1%)
CYB5R3c350C > G homozygotes 12 (7.3%) 22 (8.2%) 38 (11.8%)